Methylene blue in medicine: authorized uses and investigational applications

Methylene blue has established medical uses, but authorization belongs to a particular product and indication. An injectable antidote, a tablet designed to stain the colon, and an experimental oral treatment are different interventions, even when they contain related chemistry.

In the United States, the ProvayBlue prescribing information identifies acquired methemoglobinemia as its indication in adults and children. The European Union also authorizes a different formulation, Lumeblue, to improve visualization during colonoscopy. Neither authorization establishes that retail methylene blue drops treat an unrelated disease.

Read the authorization and evidence fields separately

Authorized use means the named product's authorization covers the indication, route, and patient group described. Off-label use means an authorized medicine is used outside its labeling. Investigational use means researchers are evaluating an application. An application can be both off-label in clinical practice and investigational in trials.

These descriptions do not rank evidence by themselves. A small trial can provide a useful signal without establishing routine benefit. Conversely, an established antidote for an uncommon emergency may be supported by clinical experience and patient series rather than the large placebo-controlled trials expected for chronic disease.

The matrix below checks named US, EU, and UK product records as of 12 September 2026. It is a clinical orientation, not an exhaustive register of every national product. For research rows, “outside reviewed labels” refers to the named methylene blue medicines above, rather than a claim about every jurisdiction or device authorization.

Clinical-use matrix

Why the route changes the clinical question

In methemoglobinemia, hemoglobin iron has been oxidized from its functional ferrous state, Fe²⁺, to ferric iron, Fe³⁺. Methylene blue participates in a reduction pathway that helps restore functional hemoglobin. The Proveblue pharmacology description explains this conversion. The clinical target is a specific blood abnormality, not a general shortage of energy. Our explanation of hospital treatment for methemoglobinemia follows that distinction in detail.

Lumeblue uses a different property: staining. Its coating delays release so dye can color the bowel lining during preparation for examination. The EMA's assessment summary reports detection in 56% versus 48% of participants in the principal comparison. The measured benefit was finding lesions, confirmed by tissue examination. It was not shrinkage of a tumor or an observed reduction in cancer deaths.

That distinction also explains why a local surgical dye injection, oral liquid, and intravenous medicine cannot be substituted merely by matching the mass of dye. Site of exposure, sterility, release properties, and the procedure determine what the product does. The details belong in injections and intravenous formulations and surgical and diagnostic applications.

What the promising trial results actually establish

The septic-shock trial provides a useful example of reading past a favorable headline. It was a single-center, placebo-controlled study in which methylene blue was added early to existing treatment. Median time until vasopressors could be stopped was 69 hours with methylene blue versus 94 hours with placebo. Mortality and ventilator duration were similar. This supports further investigation of a vasopressor-sparing effect; it does not demonstrate a survival benefit. Vasoplegia and septic-shock trials require separate interpretation because their patients and causes of circulatory failure differ.

Neurological research adds a formulation problem. The 891-participant phase 3 LMTM trial studied leuco-methylthioninium bis(hydroxymethanesulfonate), a reduced methylthioninium formulation, over 15 months in mild-to-moderate Alzheimer's disease. Its prespecified primary analyses found no benefit on cognition or activities of daily living at the tested higher doses versus the low-dose control. Subgroup interpretations do not replace that primary result, and the formulation is not an ordinary bottle of methylene blue.

This is one trial within a continuing research program, not a verdict on every later compound or study. Read the Alzheimer's trial analysis for the evolving evidence. The same discipline applies to cancer research: killing cultured cells, improving an imaging endpoint, and helping patients live longer are different findings.

Safety is part of the formulation, not a separate checkbox

The US injection label warns about serious serotonin syndrome with serotonergic medicines and opioids, contraindicates use in G6PD deficiency, and describes interference with pulse-oximeter readings. These are practical reasons for clinicians to assess the actual medicine list and laboratory context. An apparently lower oxygen reading after exposure does not by itself show that oxygen delivery has worsened.

The UK SmPC additionally specifies contraindications for chlorate poisoning and certain nitrite-related circumstances. “Antidote” therefore does not mean appropriate for every poisoning. Severe breathing difficulty, collapse, or sudden confusion requires urgent assessment, not a home trial of blue dye.

For a proposed treatment, identify the exact product, route, diagnosis, and outcome first. Bring those details to the clinical conversation checklist and consult the side effects and contraindications guide. The useful question is whether evidence supports that specific intervention in that specific setting.